Anti-Xa Assay in Pulmonary Embolism Clinical Trial
Official title:
Anti-Xa Assay Correlation to the Efficacy and Safety of Enoxaparin in the Treatment of Pulmonary Embolism
The aim of the present study is to monitor anticoagulant therapy by anti-Xa assay and correlate its level to the efficacy and safety of enoxaparin in the treatment of pulmonary embolism.
This prospective randomized trial was conducted on 42 patients 18 years of age or older in
ICU diagnosed to have pulmonary embolism and confirmed by the presence of intraluminal
filling defect in CT pulmonary angiography and treated with subcutaneous enoxaparin 1
mg/kg/12 hours. The study was conducted from August 2013 to September 2016.
All the patients were examined daily over a period of 4 weeks for symptoms and signs of
recurrent pulmonary embolism (recurrent pulmonary embolism was diagnosed if the repeat CT
angiography revealed a new sudden arterial branch cutoff or a new intraluminal filling
defect that was not present on the first angiogram), Platelet count (patients with platelet
count less than 50,000/mm3 or those with bleeding and platelet count between 50,000 and
100,000/mm3 are considered having severe thrombocytopenia), bleeding (defined as major overt
bleeding requiring blood transfusion > 2 units or marked hemoglobin drop > 2 gm/dl or if the
bleeding was intracranial or retroperitoneal) and death (defined as all deaths occurring
within the 4 weeks of the study) , Then the results were correlated to anti-Xa assay.
;